ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Esketamine

Also written as “Esketamine 84 mg”, “Esketamine 56 mg” and “AM-101”.

Its studies are mostly in Depressive Disorder, Treatment-Resistant · Depressive Disorder, Major · Tinnitus · Depression · Substance-Related Disorders, led by 3 companies.

Drug pageEsketamine: every studyAll 243 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 21, 202045 company-led studies, 2 open or runningNext primary completion: Dec 27, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only412 open or runningphase 4since Oct 21, 2020Jul 11, 2012Dec 27, 2028phase 3 · NCT07716098
Celon Pharmaits history only30 open or runningphase 2since May 21, 2019Jan 8, 2018none ahead
Chengdu Brilliant Pharmaceutical10 open or runningphase 3since Sep 21, 2023Sep 21, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chengdu Brilliant Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 21, 2023First study: phase 3 study in LaparoscopyFirst studyNCT06092684 · 358 enrolled · China

TargetBeta

“Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule

Other programs on the same 7 targets

ProgramCompanyFurthest phaseStudies
MemantineruleAbbViephase 429

Studies

The one study Chengdu Brilliant Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06092684Laparoscopy · China3CompletedMar 19, 2024358

How it is read

Names in the registry

  • “Esketamine”, 30 entries
  • “Esketamine 84 mg”, 8 entries
  • “Esketamine 56 mg”, 7 entries
  • “AM-101”, 5 entries
  • “Esketamine 28 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.